India's longevity boom must stop treating women as an afterthought

The article argues that the longevity and health industry is failing women by relying on data models based primarily on male biology. It calls for increased investment in 'femtech' that addresses the specific hormonal and health transitions women face during midlife.
Why it matters
It highlights a systemic gender bias in medical research and product development, suggesting a significant economic opportunity in addressing these health gaps.
Walk through most preventive health protocols today, the panels, the risk scores, the reference ranges used to flag what counts as normal, and a lot of it traces back to studies built predominantly on male cohorts. Add midlife women into that picture and the gaps widen. A woman in her forties reporting fatigue, brain fog, joint pain or disrupted sleep often finds that standard panels do not fully capture what she is experiencing, and the hormonal driver behind it can go unexamined. She sits in an uncomfortable middle: too complex for general wellness, not quite a fit for gynaecology, which is usually built around fertility and reproductive years rather than the decade of hormonal transition that follows.That is a real gap, and worth naming clearly.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in